Rockefeller Capital Management L.P. Buys 4,006 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Rockefeller Capital Management L.P. boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 250,410 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,006 shares during the quarter. Rockefeller Capital Management L.P. owned about 0.41% of Jazz Pharmaceuticals worth $30,838,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth about $25,000. Quadrant Capital Group LLC raised its holdings in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 101 shares in the last quarter. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $28,000. Allianz SE bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $29,000. Finally, Jones Financial Companies Lllp grew its holdings in shares of Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 130 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 1.5 %

NASDAQ JAZZ opened at $100.50 on Monday. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The company’s 50-day moving average price is $129.67 and its 200-day moving average price is $122.77. The stock has a market cap of $6.10 billion, a PE ratio of 14.15, a PEG ratio of 1.04 and a beta of 0.42. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Analyst Ratings Changes

JAZZ has been the topic of a number of recent research reports. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Morgan Stanley reaffirmed an “overweight” rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Truist Financial lifted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. JPMorgan Chase & Co. upped their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Barclays reiterated an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average price target of $187.71.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares of the company’s stock, valued at $53,785,088.64. This represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock worth $4,023,305 in the last three months. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.